

BIOCON BIOLOGICS GREECE SINGLE MEMBER P.C.**BALANCE SHEET AS AT MARCH 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>March 31, 2026</u>	<u>March 31, 2025</u>
ASSETS			
Non-current assets			
Right of use assets		97	150
Financial assets			
Other financial assets	4	2	1
Deferred tax asset (net)		2,596	2,520
Total non-current assets		2,695	2,671
Current assets			
Inventories	1	3,097	2,644
Financial assets			
(i) Trade receivables	2	10,547	6,115
(ii) Cash and cash equivalents	3	972	341
Other current assets	5	80	73
Total current assets		14,696	9,173
TOTAL		17,391	11,844
EQUITY AND LIABILITIES			
Equity			
Equity share capital	6	-	-
Other equity	7	351	186
Total equity		351	186
Non-current liabilities			
Lease liabilities		49	98
Total current liabilities		49	98
Current liabilities			
Financial liabilities			
(i) Trade payables	8	14,884	9,200
(ii) Lease liabilities		54	56
Income-tax liability (net)		1,697	1,943
Provisions	9	21	22
Other liabilities	10	335	339
Total current liabilities		16,991	11,560
TOTAL		17,391	11,844

BIOCON BIOLOGICS GREECE SINGLE MEMBER P.C.**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

		Year ended	Year ended
	<u>Notes</u>	March 31, 2026	March 31, 2025
Income			
Revenue from operations	11	10,696	9,802
Other operating income	12	(8)	1
Total revenue		10,688	9,803
Expenses			
Purchases of traded goods	13	8,953	7,119
Changes in inventories of traded goods	14	(453)	392
Employee benefits expense	15	1,127	1,118
Depreciation		53	53
Finance Costs	16	9	12
Other expenses	17	777	917
Total expenses		10,466	9,611
Exceptional Expense		13	-
Profit before tax		209	192
Tax expense			
Current tax		120	2,549
Deferred Tax		(76)	(2,505)
Total tax expense		44	44
Profit for the year		165	148

BIOCON BIOLOGICS GREECE SINGLE MEMBER P.C.**STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2026	Year ended March 31, 2025
I Cash flows from operating activities		
Profit after tax	165	148
<u>Adjustments to reconcile profit before tax to net cash flows:</u>		
Depreciation and amortisation (net)	53	53
Unrealised foreign exchange (gain)/loss	(8)	1
Finance costs	9	12
Tax expense	44	44
Operating profit before working capital changes	263	258
Movements in working capital		
(Increase) in trade receivables	(4,434)	(1,032)
(Increase)/decrease in trade inventories	(453)	392
(Increase) in loans and advances and other assets	(7)	(37)
Increase in trade payable, other liabilities and provisions	5,680	1,369
Cash generated from operations	1,050	950
Direct taxes paid	(366)	(634)
Net cash flow generated from operating activities	684	316
II Cash flows from financing activities		
Repayment of lease liabilities	(60)	(64)
Net cash flow (used) in financing activities	(60)	(64)
III Net increase in cash and cash equivalents (I + II)	623	252
IV Effect of exchange differences on cash and cash equivalents held in foreign currency	8	(1)
V Cash and cash equivalents at the beginning of the period	341	91
VI Cash and cash equivalents at the end of the period	972	341
Reconciliation of cash and cash equivalents as per statement of cash flow		
Cash and cash equivalents		
Balances with banks - on current accounts	972	341
Total cash and cash equivalents [Refer note 3]	972	341

BIOCON BIOLOGICS GREECE SINGLE MEMBER P.C.**Notes to financial statements for the year ended March 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	March 31, 2026	March 31, 2025
1. Inventories		
Finished Goods	3,097	2,644
	3,097	2,644
2. Trade receivables		
Other Receivables		
Outstanding for a period less than six months from the date they are due for payment	10,553	6,115
Unsecured, considered good	(6)	
Allowance for credit loss	10,547	6,115
3. Cash and cash equivalents		
Balances with banks:		
On current accounts	972	341
	972	341
4. Other non-current financial assets		
Deposits	2	1
	2	1
5. Other current assets		
Advance to suppliers	74	72
Prepayments	6	1
	80	73
6. Share capital		
Authorised		
Issued, subscribed and fully paid-up		
Equity share 1 Common stock of EUR 1 each	-	-
	-	-
7. Other equity		
Surplus/(deficit) in the statement of profit and loss		
Balance as per the last financial statements	186	38
Profit for the year	165	148
Net surplus in the statement of profit and loss	351	186
Total other equity	351	186
8. Trade payables	14,884	9,200
9. Provisions		
Current		
Compensated absences	21	22
	21	22
10. Other liabilities		
Current liabilities		
Statutory liabilities	205	215
Employee related payables	130	124
	335	339

BIOCON BIOLOGICS GREECE SINGLE MEMBER P.C.**Notes to financial statements for the year ended March 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2026	Year ended March 31, 2025
11. Revenue from operations		
Sale of Products		
Traded Goods	10,486	9,610
Sale of Services		
Support service cross charge to Group Companies	210	192
	10,696	9,802
12. Other operating income		
Foreign exchange fluctuations, net	(8)	1
	(8)	1
13. Purchases of traded goods	8,953	7,119
14. Changes in inventories of traded goods		
Inventory at the beginning of the year		
Traded goods	2,644	3,036
Inventory at the end of the year		
Traded goods	3,097	2,644
	(453)	392
15. Employee benefits expense		
Salaries, wages and bonus	1,083	1,084
Employee stock compensation expense	22	5
Staff welfare expenses	22	29
	1,127	1,118
16. Finance Costs		
Interest on lease obligation	9	12
	9	12
17. Other expenses		
Rates and taxes	13	3
Rent	25	41
Distribution cost	150	222
Legal and professional fees	147	258
Repair and Maintenance	2	5
Travelling and conveyance	126	135
Sales promotion expenses	283	230
Freight outwards and clearing charges	-	(1)
Printing and stationery	3	4
Communication expenses	5	4
Miscellaneous expenses	17	16
Provision/(reversal) for doubtful debts, net	6	-
	777	917